Thrombophilia

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 2, 2013, Pages 177-187

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD; COMPLICATION; FEMALE; HUMAN; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOSIS; ARTICLE; PREGNANCY COMPLICATION; VEIN THROMBOSIS;

FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 84893357677     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612474840m     Document Type: Article

References (82)

1. Griffin JH Evatt B Zimmerman TS Kleiss AJ Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981; 68(5):1370-1373.
2. Schwarz HP Fischer M Hopmeier P Batard MA Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984; 64(6):1297-300.
3. Comp PC Nixon RR Cooper MR Esmon CT. Familial protein S deficiency is associated with recurrent thrombosis. J Clin Invest. 1984; 74(6):2082-2088.
4. Dahlback B Carlsson M Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993; 90(3):1004-1008.
5. Bertina RM Koeleman BP Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369(6475):64-67.
6. Poort SR Rosendaal FR Reitsma PH Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88(10):3698-3703.
7. Rosendaal FR Reitsma PH. Genetic of venous thrombosis. J Thromb Haemost. 2009; 7(suppl 1):301-304.
8. Mahmoodi BK Brouwer JL Ten Kate MK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost. 2010; 8(6):1193-1200.
9. Rossi E Ciminello A Za T Betti S Leone G De Stefano V. In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. Thromb Haemost. 2011; 106(4):646-654.
10. Lijfering WM Veeger NJ Middeldorp S, et al. A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. Blood. 2009; 114(10):2031-2036.
11. Vossen CY Conard J Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost. 2004; 2(9):1526-1532.
12. de Moerloose P Boehlen F Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010; 36(1):7-17.
13. Kraiem I Guermazi S Ben Abid H Meddeb B. Dysfibrinogenemia and thrombosis. A case report. Tunis Med. 2010; 88(10):757-760.
14. Travlou A Gialeraki A Merkouri E Politou M Sfyridaki A Neerman-Arbez M. Coexisting dysfibrinogenemia (gamma Arg275His) and FV Leiden associated with thrombosis (Fibrinogen Crete). Thromb Res. 2010; 126(2):e162-e164.
15. Dentali F Squizzato A Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph-myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009; 113(22):5617-5623.
16. Pengo V Banzato A Bison E Bracco A Denas G Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost. 2012; 38(4):322-327.
17. De Stefano V. Inherited thrombophilia and life-time risk of venous thromboembolism: is the burden reducible? J Thromb Haemost. 2004; 2(9):1522-1525.
18. Vossen CY Conard J Fontcuberta J, et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European prospective cohort on thrombophilia (EPCOT). J Thromb Haemost. 2005; 3(3):459-464.
19. Margaglione M Grandone E. Population genetics of venous thromboembolism. A narrative review. Thromb Haemost. 2011; 105(2):221-231.
20. Marlar RA Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost. 1990; 16(4):299-309.
21. Finazzi G Caccia R Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost. 1987; 58(4):1094.
22. Christiansen SC Cannegieter SC Koster T Vandenbroucke JP Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005; 293(19):2352-2361.
23. Miyakis S Lockshin MD Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306.
24. Lidegaard O Lokkegaard E Svendsen AL Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. Br Med J. 2009; 339: b2890.
25. Lidegaard O Nielsen LH Skovlund CW Skjeldestad FE Lokkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. 2011; 343: d6423.
26. Jick S Kaye JA Li L Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007; 76(1):4-7.
27. Fleischer K van Vliet HA Rosendaal FR Rosing J Tchaikovski S Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res. 2009; 123(3):429-435.
28. van Hylckama Vlieg A Helmerhorst FM Vandenbroucke JP Doggen CJ Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921.
29. Cole JA Norman H Doherty M Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007; 109(2 pt 1):339-346.
30. Kemmeren JM Algra A Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ. 2001; 323(7305):131-134.
31. Parkin L Sharples K Hernandez RK Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ. 2011; 342: d2139.
32. Jick SS Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ. 2011; 342: d2151.
33. Gronich N Lavi I Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. Can Med Ass J. 2011; 183(18):E1319-E1325.
34. Rosing J Tans G. Effects of oral contraceptives on hemostasis and thrombosis. Am J Obstet Gynecol. 1999; 180(6 pt 2):S375-S382.
35. Middeldorp S Meijers JC van den Ende AE, et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost. 2000; 84(1):4-8.
36. Tans G Curvers J Middeldorp S, et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost. 2000; 84(1):15-21.
37. Alhenc-Gelas M Plu-Bureau G Guillonneau S, et al. Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives. J Thromb Haemost. 2004; 2(9):1594-600.
38. Tchaikovski SN Rosing J. Mechanisms of estrogen-induced venous thromboembolism. Thromb Res. 2010; 126(1):5-11.
39. Odlind V Milsom I Persson I Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand. 2002; 81(6):482-490.
40. Wiegratz I Kutschera E Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception. 2003; 67(1):25-32.
41. Raps M Helmerhorst F Fleischer K, et al. Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives. J Thromb Haemost. 2012; 10(6):992-997.
42. Wu O Robertson L Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and economic assessment of thrombophilia screening (TREATS) study. Thromb Haemost. 2005; 94(1):17-25.
43. Conard J Plu-Bureau G Bahi N Horellou MH Pelissier C Thalabard JC, Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception. 2004; 70(6):437-441.
44. van Hylckama Vlieg A Helmerhorst FM Rosendaal FR. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol. 2010; 30(11):2297-2300.
45. Caine YG Bauer KA Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost. 1992; 68(4):392-395.
46. Scarabin PY Alhenc-Gelas M Plu-Bureau G Taisne P Agher R Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol. 1997; 17(11):3071-3078.
47. Nelson HD Humphrey LL Nygren P Teutsch SM Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288(7):872-881.
48. Scarabin PY Oger E Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003; 362(9382):428-432.
49. Oger E Alhenc-Gelas M Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol. 2003; 23(9):1671-1676.
50. Hoibraaten E Qvigstad E Arnesen H Larsen S Wickstrom E Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000; 84(6):961-967.
51. Herrington DM Vittinghoff E Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol. 2002; 22(6):1012-1017.
52. Rosendaal FR Vessey M Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol. 2002; 116(4):851-854.
53. Olie V Canonico M Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010; 17(5):457-463.
54. Canonico M Oger E Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007; 115(7):840-845.
55. Straczek C Oger E Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005; 112(22):3495-3500.
56. Olie V Plu-Bureau G Conard J Horellou MH Canonico M Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011; 18(5):488-493.
57. Heit JA Kobbervig CE James AH Petterson TM Bailey KR Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005; 143(10):697-706.
58. James AH Jamison MG Brancazio LR Myers ER. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006; 194(5):1311-1315.
59. Jacobsen AF Skjeldestad FE Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost. 2008; 6(6):905-912.
60. Ray JG Chan WS. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation. Obstet Gynecol Surv. 1999; 54(4):265-271.
61. Jacobsen AF Skjeldestad FE Sandset PM. Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium--a register-based case-control study. Am J Obstet Gynecol. 2008; 198(2):233.
62. Voke J Keidan J Pavord S Spencer NH Hunt BJ. The management of antenatal venous thromboembolism in the UK and Ireland: a prospective multicentre observational survey. Br J Haematol. 2007; 139(4):545-558.
63. Rova K Passmark H Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization: an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012; 97(1):95-100.
64. Brill-Edwards P Ginsberg JS Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N Engl J Med. 2000; 343(20):1439-1444.
65. De Stefano V Martinelli I Rossi E, et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol. 2006; 135(3):386-391.
66. White RH Chan WS Zhou H Ginsberg JS. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism. Thromb Haemost. 2008; 100(2):246-252.
67. Pabinger I Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol. 1996; 16(6):742-748.
68. Conard J Horellou MH Van Dreden P Lecompte T Samama M. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost. 1990; 63(2):319-320.
69. McColl MD Ramsay JE Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997; 78(4):1183-1188.
70. Robertson L Wu O Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006; 132(2):171-196.
71. Serour GI Aboulghar M Mansour R Sattar MA Amin Y Aboulghar H. Complications of medically assisted conception in 3,500 cycles. Fertil Steril. 1998; 70(4):638-642.
72. Mara M Koryntova D Rezabek K, et al. Thromboembolic complications in patients undergoing in vitro fertilization: retrospective clinical study. Ceska Gynekol. 2004; 69(4):312-316.
73. Chan WS Dixon ME. The “ART” of thromboembolism: a review of assisted reproductive technology and thromboembolic complications. Thromb Res. 2008; 121(6):713-726.
74. Di Nisio M Rutjes AW Ferrante N Tiboni GM Cuccurullo F Porreca E. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood. 2011; 118(10):2670-2678.
75. Nelson-Piercy C Powrie R Borg JY, et al. Tinzaparin use in pregnancy: an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol. 2011; 159(2):293-299.
76. Byrd LM Shiach CR Hay CR Johnston TA. Osteopenic fractures in pregnancy: is low molecular weight heparin (LMWH) implicated? J Obstet Gynaecol. 2008; 28(5):539-542.
77. Hellgren M Tengborn L Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 1982; 14(2):127-141.
78. Tiede A Tait RC Shaffer DW, et al. Antithrombin alfa in hereditary antithrombin deficient patients: a phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost. 2008; 99(3):616-622.
79. Pernod G Biron-Andreani C Morange PE, et al. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc. 2009; 34(3):156-203.
80. Baglin T Gray E Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010; 149(2):209-220.
81. Kearon C. Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism. Curr Opin Hematol. 2012; 19(5):363-370.
82. Jenkins PV Rawley O Smith OP O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol. 2008; 157(6):653-663.